New study tests resilience training for lymphoma survivors
NCT ID NCT07014293
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 6 times
Summary
This study tests whether a mind-body resilience group program can help lymphoma survivors cope better after finishing treatment. Researchers will enroll 254 adults who are within two years of completing curative therapy. Participants will either receive enhanced usual care or join a program that teaches relaxation, stress recognition, and positive thinking skills. The goal is to see if the program reduces anxiety and improves coping.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mind-body resilience group program (SMART3RP-Lymphoma) including relaxation response, cognitive behavioral therapy, and positive psychology
- What this could lead to
- If it works, this could provide a practical, non-drug way to help lymphoma survivors manage stress and improve their quality of life after treatment.
- What could go wrong
- This is a relatively small, early-stage trial testing a behavioral program, so results may not apply to all survivors. The program requires active participation and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 254 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * English speaking adult (18 years or older at enrollment) * At least 6-months post-lymphoma diagnosis and within 2 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other) Exclusion Criteria: * Active Psychiatric or cognitive comorbidity as determined by site PI or treating clinician * Unwilling or unable to participate using telehealth platform
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mass General Brigham
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Drug attack on Hard-to-Treat lymphomas
- Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
- Can a calming drug make cord blood transplants safer?
- Can a Nine-Week group program help blood cancer patients grow through trauma?
- Do social factors decide who completes lymphoma treatment?
- Smartphone app and wearable sensor team up to catch infections early in cancer care